(Q53615123)

16 May 2018

title

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. (English)

1 reference

16 May 2018

1 reference

1 reference

1 reference

Rodney P Rocconi

1

1 reference

16 May 2018

Ashley S Case

2

1 reference

16 May 2018

J Michael Straughn

3

1 reference

16 May 2018

Jacob M Estes

4

1 reference

16 May 2018

Edward E Partridge

5

1 reference

16 May 2018

language of work or name

English

0 references

publication date

1 August 2006

1 reference

16 May 2018

number of pages

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

16 May 2018

volume

107

1 reference

16 May 2018

issue

3

1 reference

16 May 2018

page(s)

536-543

1 reference

16 May 2018

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Treatment of recurrent ovarian cancer: increasing options--"recurrent" results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Resource utilization for ovarian cancer patients at the end of life: how much is too much?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Future of end-of-life care: the managed care organization perspective

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Optimizing primary chemotherapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.22045

1 reference

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22045

7 January 2021

Identifiers

DOI

10.1002/CNCR.22045

1 reference

16 May 2018

1 reference

16 May 2018